Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
67.8M
-
Number of holders
-
51
-
Total 13F shares, excl. options
-
19.5M
-
Shares change
-
-1.25M
-
Total reported value, excl. options
-
$44.6M
-
Value change
-
+$735K
-
Put/Call ratio
-
1.91
-
Number of buys
-
33
-
Number of sells
-
-11
-
Price
-
$2.29
Significant Holders of Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (CRVS) as of Q2 2023
61 filings reported holding CRVS - Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share as of Q2 2023.
Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (CRVS) has 51 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 19.5M shares
of 67.8M outstanding shares and own 28.76% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (6.94M shares), ADAMS STREET PARTNERS LLC (3.28M shares), SAMLYN CAPITAL, LLC (2.11M shares), BVF INC/IL (1.37M shares), VANGUARD GROUP INC (1.3M shares), BlackRock Inc. (532K shares), Artal Group S.A. (500K shares), RENAISSANCE TECHNOLOGIES LLC (490K shares), GEODE CAPITAL MANAGEMENT, LLC (342K shares), and MARSHALL WACE, LLP (299K shares).
This table shows the top 51 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.